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Introduction: Surgical resection is the only curative treatment for gastric cancer. However, the overall
prognosis of gastric adenocarcinoma is poor and advanced disease may even make surgical treatment
impossible. It has been theoretically proposed that administration of chemotherapy before surgical
resection may down-stage the disease state and facilitate resectability especially in locally-advanced
tumors. Aim: We wanted to assess the effect of administration of neoadjuvant chemotherapy on tu-
mor resectability in patients with locally-advances gastric adenocarcinoma. Materials and methods:
During a randomized-controlled trial, we divided 60 patients with locally-advanced gastric adenocar-
cinoma into two groups of neoadjuvant chemotherapy and surgery (case) versus surgery alone (control).
Because of patient dropouts, we analyzed the results for 22 and 29 patients in case and control groups
respectively. The study period was March 21, 2011 to March 20, 2014. A non-randomized set of 23 pa-
tients were also added to the control group (Multi-center analysis). The analysis was repeated for non-
randomized patients (22 case patients versus 52 control patients). Results: The mean age of patients in
case and control groups was 58.3 ± 9.1 and 59.7 ± 8.7 years of age respectively (p > 0.05). Male to female
ratio was 15/7 and 41/11 in case and control groups respectively (p > 0.05). In Randomized patients, 19
patients (86.4%) were resectable in case group; while 16 patients (55.2%) were resectable in control
group (p < 0.05). Multicenter analysis also revealed resectability in 19 patients (86.4%) and 31 patients
(59.6%) of case and control groups respectively (p < 0.05). Conclusion: We conclude that neoadjuvant
chemotherapy could increase tumor resectability rate in patients with locally-advanced gastric adeno-
carcinoma. However, further studies are necessary to conﬁrm the effect of this modality on patients'
overall survival.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Adenocarcinoma is the most common primary malignant
gastric neoplasmwhich accounts for 95% of gastric cancers. In 1930,spital, General Surgery, Tabriz
an).
by Elsevier Ltd. All rights reservedgastric cancer was among the leading causes of cancer death in the
United States of America but today, it is not even included among
the top ten causes [1]. However, Iranian studies suggest that inci-
dence of esophageal cancer shows a declining pattern while the
incidence of gastric, colon and breast cancer have a growing pattern
in recent decade [2]. Furthermore, a population-based study has
estimated that esophageal and gastric cancers have high rates in.
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respectively [3].
Surgical resection is the only curative treatment for gastric
cancer [1,4e7]. The aim of curative surgical resection is R0 resec-
tion. Thus, all proximal, distal and radial margins should be nega-
tive and an adequate lymphadenectomy performed [1,7]. The
standard operation for gastric cancer is radical subtotal gastrec-
tomy. However, total gastrectomy is performed when it is required
for R0 resection [1,4,7e9].
In general, the survival of gastric adenocarcinoma is poor
because most surgical patients have stage II disease or greater. Even
after potentially curative surgery, overall survival at 5 years for
patients with gastric adenocarcinoma remains as low as 20%e30%
[1,7]. Advanced gastric cancer may even make surgical treatment
impossible and lead to unnecessary laparotomy [1,7,10].
Theoretically, administration of chemotherapy before surgical
resection can address micrometastatic lesions and down-stage the
disease. It also allows for an assessment of chemotherapeutic efﬁ-
cacy in patients with measurable disease (primary or perigastric
nodal disease) on imaging [7,11]. Some concerns regarding preop-
erative therapy are progression of disease before resection and the
potential for surgery-preventing toxicity. In reality, the patients
who progress on preoperative therapy may be spared unnecessary
laparotomy, because their disease is likely beyond surgical therapy
at presentation. Toxicity remains an issue, because the platinum-
based regimens that are often used can be difﬁcult to tolerate [7].
Because of poor prognosis of gastric adenocarcinoma, neo-
adjuvant chemotherapy was proposed to be administered to pa-
tients with locally-advanced disease [1,4]. A number of trials have
been conducted to assess the effect of neoadjuvant chemotherapy
on survival of patients with locally-advanced gastric adenocarci-
noma but none of them is conclusive [7]. The role of neoadjuvant
therapy for resectable disease was also examined in several recent
prospective studies [12]. The main criticisms of literature studies
are poor preoperative staging, limited statistical power and un-
predictable efﬁcacy of chemotherapy regimens.
In the present study, we wanted to assess the effectiveness of
preoperative chemotherapy on tumor resectability in patients with
locally-advanced gastric adenocarcinoma. It is still unclear whether
neoadjuvant chemotherapy is beneﬁcial in gastric adenocarcinoma
or not. Moreover, the subgroups of patients who might have more
survival beneﬁts from neoadjuvant chemotherapy are not clearly
identiﬁed. In the cases of resectable disease, survival beneﬁt is the
primary outcome of interest. However, in locally-advanced disease,
resectability is a potential concern because surgical resection is the
only curative treatment modality.
2. Methods
The aim of this study was to assess the effect of neoadjuvant
chemotherapy on increasing the rate of resectability in patients
with locally-advances gastric adenocarcinoma. We designed a
randomized-controlled trial to evaluate the outcome of preopera-
tive chemotherapy on resectability of locally-advanced gastric
tumors.
The state of locally-advanced gastric tumor was assessed by the
preoperative abdominopelvic computed tomography (CT). We used
64-slice multi-detector CT for our preoperative assessment in all
study patients. Presence of peri-gastric lymph node involvement in
the preoperative CT scans was considered locally-advanced tumor.
We studied only tumors with preoperative diagnosis of adenocar-
cinoma. The preoperative diagnosis was made by histopathological
examination of endoscopic biopsies.
All patients with gastric adenocarcinoma who had locally-
advanced tumor conﬁrmed by computed tomography werechosen and assessed for eligibility. The study period was March 21,
2011 to March 20, 2014. The inclusion and exclusion criteria were
considered to select the study patients. The inclusion criteria con-
sisted of being younger than 70 years of age, conﬁrmation of
adenocarcinoma by histopathological examination of endoscopic
gastric tissue biopsies, the presence of peri-gastric lymph node
involvement in CT scan (i.e., locally-advanced tumor) and being
resectable based on CT ﬁndings. The exclusion criteria consisted of
being older than 70 years of age, pathologies other than adeno-
carcinoma, presence of distant metastasis on preoperative CT scans,
any contraindication to chemotherapy and history of previous
chemoradiation for any reason. Locally-advanced gastric tumors
are deﬁned by tumor size (T) and lymph node involvement (N). T3
and N positive tumors are considered locally-advanced. Deﬁning
locally-advanced gastric adenocarcinoma preoperatively necessi-
tates endoscopic ultrasound (EUS) to assess the tumor size (T) and
lymph node involvement (N), i.e., radiological staging. Lymph node
involvement should be conﬁrmed by EUS-FNA (Endoscopic
Ultrasound-guided Fine Needle Aspiration). Stage II gastric tumors
which are T3N0, T1N2 and T2N1 are considered locally-advanced.
In addition, stages IIIA and IIIB tumors with TNMs of T2N2, T3N1
and T3N2 are considered locally-advanced. Because we do not have
EUS at our institution, we considered per-gastric lymph node
involvement in preoperative CT scan as Nþ tumors that are locally-
advanced [1,5].
After the enrollment of patients with locally-advanced gastric
adenocarcinoma and consideration of inclusion and exclusion
criteria, 60 patients were selected for the study. The study patients
were randomly divided into two groups of case and control using
the website www.randomizer.org. Each group consisted of 30 pa-
tients. All patients were studied at Imam Reza Hospital, the tertiary
and referral center of East Azerbaijan, Iran. This institution is
afﬁliated to Tabriz University of Medical Sciences and the main
wards of the Department of General and Vascular Surgery are
located there.
The patients of the case group delivered neoadjuvant chemo-
therapy while the patients in the control group did not. The case
patients received a combined chemotherapy regimen consisted of
docetaxel 75 mg/m2, IV, 1 h infusion on ﬁrst day, cisplatin 75 mg/
m2, IV, 2 h infusion on ﬁrst day and 5-ﬂuorouracil 750 mg/m2/day,
IV continuous infusion, days 1e5. The regimen was repeated every
3 weeks for 6 courses. The control patients did not get any
chemotherapy regimens preoperatively. They also did not get pla-
cebo treatment. The reason for not using placebo regimen for the
control group was that the main therapy in gastric cancer is sur-
gery. Delaying surgical treatment for placebo administration could
be hazardous to patients and that is why this study could not be
controlled by placebo. In addition, we could not perform a blinded
study because the patients were aware whether they have received
neoadjuvant chemotherapy or not.
We did surgical exploration for all patients in case and control
groups to assess the resectability and then continued with possible
gastric resection. We performed R0D1 or R0D2 sub-total or total
gastrectomy as a curative treatment in patients with gastric cancer.
Placement of jejunostomy tube was not mandatory and was
considered based on the surgeons' judgment of the patient's
nutritional and physiologic status. During the present study, the
patients in case group received neoadjuvant chemotherapy and
underwent surgery 4e6 weeks after their last course of chemo-
therapy. The patients in control group underwent surgery as soon
as they entered the trial. The allocation of patients to case and
control groups is illustrated in Fig. 1 as the follow diagram or
CONSORT of the study (Consolidated Standard of Reporting Trials).
We conducted control CT scans for the patients in case group
after completion of their neoadjuvant chemotherapy courses. The
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by 30% ormore and decline of peri-gastric lymph node involvement
by 30% or more (cut-off points of 30%). The CTs before and after
neoadjuvant chemotherapy was reviewed by a single radiologist
who was expert in computed tomography.
The resectability of the tumor was compared between two
groups of the study. The resectability was considered as the pri-
mary outcome of the study. The secondary outcomes were also
compared between two groups. They consisted of total admission
days, admission days in surgical intensive care unit (SICU), post-
operative mechanical ventilatory support, days of nil per os (NPO),
postoperative day of removal of nasogastric tube, duration of
operation, need for intraoperative blood transfusion, need for
postoperative blood transfusion, occurrence of postoperative
metabolic acidosis, need for central venous catheter placement,
postoperative day of ambulation and in-hospital morbidity and
mortality. In-hospital morbidity consisted of wound dehiscence,
wound infection, bleeding, need for reoperation etc.
The background variables were age, sex, primary symptoms,
endoscopic ﬁndings, familial history of gastrointestinal cancer,
preoperative hemoglobin concentration, preoperative anemia,
history of dyspepsia, history of peptic ulcer disease, history of
antiulcer treatment, history of Helicobacter pylori (H. pylori) infec-
tion, history of receiving H. pylori treatment regimens, past medical
history, past surgical history, past drug history, history of cigarette
smoking, history of hooka smoking and history of opiate use.
Intraoperative ﬁndings were recorded for all study patients.
They included the type of operation, duration of operation (previ-
ously mentioned as a secondary outcome), extent of lymphade-
nectomy, resection of adjacent involved organs (such as spleen,
transverse colon, and tail of pancreas), location of tumor and
placement of feeding jejunostomy. The types of operation wereFig. 1. Follow diagram for randomized allocationtotal, subtotal or proximal gastrectomy. The resections were R0 and
lymphadenectomies were either D1 or D2.
In the cases of resectable gastric adenocarcinoma, the speci-
mens were sent for histopathological analysis. The pathological
staging was done by TNM system based on deﬁnitions of Interna-
tional Union against Cancer (IUAC) and American Joint Committee
on Cancer (AJCC). The grading of the tumors was also reported for
the specimens in three categories: well-differentiated, moderately
differentiated and poorly-differentiated. The histological classiﬁ-
cation was also presented by Lauren classiﬁcation system: intesti-
nal type, diffuse type, and unclassiﬁed.
For the purpose of including patients from other institutions, we
recruited patients of locally-advanced gastric adenocarcinoma from
Sina Hospital which is also afﬁliated to Tabriz University of Medical
Sciences, Tabriz, Iran. We considered the study inclusion and
exclusion criteria for these patients and enrollment was done
during the same time period but allocation was not randomized.
The entire patient selection was a multi-center non-randomized
clinical trial without placebo. Fig. 2 illustrates the follow diagram
for the patients from Imam Reza and Sina hospitals.
We used descriptive statistics to explain the frequencies of
background variables. We used mean ± SD (Standard Deviation)
and frequency (%). The comparison of background variables be-
tween two groups were done by independent sample t-test and
chi-square test for scale and dichotomous variables respectively.
The comparative analyses between primary and secondary out-
comes were also done by independent sample t-test and chi-square
test for scale and dichotomous variables respectively. All statistical
analyses were done by SPSS software 19.0.
Informed consent was obtained from all study patients prior to
their enrollment to the study. According to Helsinki declaration, all
patients had the right to leave the study anytime they wished. Wes of patients at Tabriz Imam Reza hospital.
Fig. 2. Follow diagram of all study patients recruited from Tabriz Imam Reza and Sina hospitals (Multi-center recruitment).
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will be allocated to case or control groups randomly. They were
aware that participation in the trial would not expose them to
increased risk and they would receive the standard treatment
either they were allocated to case or control groups. The patients
were assured that the study would not pose additional expenses to
them.
The study of this protocol was reviewed by the research com-
mittee of the Tabriz Faculty of Medicine for dissertations and ethics
committee of the Research Vice Chancellor Ofﬁce, Tabriz University
of Medical Sciences, Tabriz, Iran. The protocol of the trial was also
registered to the Iranian Registry of Clinical Trials (IRCT) under the
number IRCT2014 053113736N1 at www.irct.ir. The study was sup-
ported by the research deputy of Faculty of Medicine, Tabriz Uni-
versity of Medical Sciences, Tabriz, Iran.3. Results
A total of 60 patients with locally-advanced gastric adenocar-
cinoma were allocated to case and control groups randomly during
this study. Dropouts were one patient and eight patients in control
and case groups respectively. The analysis for the randomized
controlled trial was done for 22 patients and 29 patients in case and
control groups respectively. The multicenter recruitment of pa-
tients from both Imam Reza and Sina hospital consisted of 22 pa-
tients and 52 patients in case and control groups respectively.The mean age of all study participants were 59.2 ± 8.8 years of
age. Themean agewas 58.3± 9.1 and 59.7 ± 8.7 years of age for case
and control groups respectively. The study patients consisted of 56
(75.7%) males and 18 (24.3%) females. The case group consisted of
15 (68.2%) males and 7 (31.8%) females; while the control group
consisted of 41 (78.8%) males and 11 (21.2%) females. There was not
any signiﬁcant difference between age and sex distribution of pa-
tients in case and control groups (p > 0.05). Table 4.1 illustrates
descriptive statistics and frequencies of background variables in the
study patients. As it is seen in Table 1, there was not any signiﬁcant
difference between background characteristics of case and control
groups.
The primary outcome of the study was the resectability of the
gastric tumor. This outcome was analyzed twice. Once we did the
comparison for the randomized patients and we did it again for all
the patients of two studied centers (Imam Reza and Sina hospitals).
The chi-square test illustrated that the resectability rate was
signiﬁcantly higher in patients who received neoadjuvant chemo-
therapy (p < 0.05). The analyses between the randomized patients
and the multi-centrally recruited patients conﬁrmed this ﬁnding.
Fig. 3 illustrates the differences between case and control patients.
In Randomized patients, 19 patients out of 22 (86.4%) were
resectable in case group; while 16 patients out of 29 (55.2%) were
resectable in control group (p ¼ 0.017). Multicenter analysis also
revealed resectability in 19 patients out of 22 (86.4%) and in 31
patients out of 52 (59.6%) in case and control groups respectively
Table 1
Background characteristics of the study patients.




Age 58.3 ± 9.1 59.7 ± 8.7 59.2 ± 8.8 0.550
Sex:
- Male 15 (68.2%) 41 (78.8%) 56 (75.7%) 0.245
- Female 7 (31.8%) 11 (21.2%) 18 (24.3)
Primary symptom:
- Dyspepsia 21 (95.5%) 46 (88.5%) 67 (90.5%) 0.323
- Others 1 (4.5%) 6 (11.5%) 7 (9.5%)
Familial history of GI cancer 2 (9.1%) 10 (19.2%) 12 (16.2%) 0.236
Diabetes mellitus 0 (0.0%) 5 (9.6%) 5 (6.8%) 0.161
Hypertension 4 (18.2%) 5 (9.6%) 9 (12.2%) 0.223
Coronary artery disease 2 (9.1%) 5 (9.6%) 7 (9.5%) 0.534
Cigarette smoking 7 (31.7%) 14 (26.9%) 21 (28.4%) 0.436
Hooka smoking 0 (0.0%) 6 (11.5%) 6 (8.1%) 0.110
Pack-years of smokingb 26.6 ± 10.7 26.4 ± 10.3 26.7 ± 11.3 0.958
Opiate use 0 (0.0%) 5 (9.6%) 5 (6.8%) 0.161
Alcohol use 0 (0.0%) 7 (13.5%) 7 (9.5%) 0.074
Anemia 4 (18.2%) 12 (23.1%) 16 (21.6%) 0.447
Preoperative hemoglobinc 11.3 ± 1.3 11.4 ± 1.4 11.4 ± 1.4 0.861
History of ulcer treatment 7 (31.8%) 27 (51.9%) 34 (45.9%) 0.091
Duration of ulcer treatmentd 25.2 ± 32.3 29.1 ± 40.3 24.2 ± 30.7 0.768
History of H. pylori infection 5 (22.7%) 18 (34.6%) 23 (31.1%) 0.234
History of H. pylori treatment 5 (22.7%) 18 (34.6%) 23 (31.1%) 0.234
Cardiovascular riske:
- Low risk 20 (90.9%) 39 (75.0%) 59 (79.7%) 0.104
- Moderate risk 2 (9.1%) 13 (25.0%) 15 (20.3%)
- High risk 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total 22 (29.7%) 52 (70.3%) 74 (100%) e
GI e Gastrointestinal; H. pylori e Helicobacter pylori.
a Scale and dichotomous variables are presented by mean ± SD and frequency (%)
respectively.
b Mean ± SD is among smokers.
c Gram per deciliter.
d Mean ± SD is among patients with positive history of ulcer treatment.
e According to American Society of Anesthesiologists (ASA); Classes I and II were
considered low risk; Class III was considered moderate risk; Classes IV and V were
considered high risk.
Table 2
Intraoperative ﬁndings in the study patients.
Intraoperative ﬁndings Case groupa Controla group Totala p-valuea
Operable 19 (86.4%) 31 (59.6%) 50 (67.6%) 0.021
Inoperable 3 (13.6%) 21 (40.4%) 24 (32.4%)
Duration 145.5 ± 37.9 119.8 ± 48.9 127.4 ± 47.1 0.031
Location:
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therapy (case group),15 patients (68.2%) had 30% ormore decline in
lymph node involvement. In addition, 14 patients (63.6%) had 30%
or more shrinkage of gastric involvement compared to the initial CT
scans obtained prior to chemotherapy.
The intraoperative ﬁndings are presented in Table 2. As it is seen,
the difference between duration of the operation was signiﬁcant
between case and control group (p ¼ 0.019). However, the higher
rate of inoperable patients in control group and subsequent
termination of the operation may have led to this observation.
Resecting adjacent organs was done in one case of control groupFig. 3. Resectability of gastric tumors in case and control groups (Note that two
comparisons are shown; left for the randomized patients and right for the multi-center
recruitment).and it was a T4 tumor with involvement of the tail of pancreas that
necessitated splenectomy and distal pancreatectomy.
Postoperative ﬁndings have been considered as secondary out-
comes. These ﬁndings are illustrated in Table 3 for case and control
groups. There was not any signiﬁcant difference between two study
groups in respect to these outcomes (p > 0.05). Two patients in
control group were dead during the hospitalization period. One of
them was operable and another was inoperable. The operable pa-
tient was dead because of postoperative splenic bleeding and he
underwent reoperation and splenectomy but he expired because of
multi-organ failure (MOF). The inoperable patient was dead
because of massive pulmonary embolus during the postoperative
admission. The in-hospital mortality rate was then 3.8% for control
group and 0.0% for case group. The difference was not statistically
signiﬁcant (p ¼ 0.491).
Histopathological ﬁndings also did not reveal any signiﬁcant
difference between two groups. In case group, 12 (54.5%), 3 (13.6%)
and 4 (18.2%) patients had well-differentiated, moderately-differ-
entiated and poorly-differentiated histology respectively. In control
group, 17 (33.3%), 5 (9.8%) and 8 (15.7%) patients had well-
differentiated, moderately-differentiated and poorly-
differentiated histology respectively (p ¼ 0.136). There were 3 pa-
tients (13.6%) and 21 patients (41.2%) in case and control groups
respectively who were inoperable and the grading was not appli-
cable for them. According to the Lauren classiﬁcation for histologic
type, 12 (54.5%), 2 (9.1%) and 5 (22.7%) patients in case group had
intestinal type, diffuse type and unclassiﬁed histology respectively.
In control group, 17 (33.3%), 4 (7.8%) and 9 (17.6%) patients had
intestinal type, diffuse type and unclassiﬁed histology respectively
(p ¼ 0.137).
TNM staging of the operable patients are presented in Table 4.
The difference between tumor size (T) was not signiﬁcant between
two groups (p ¼ 0.596). In addition, the difference between nodal
involvement and staging (based on both T and N) did not show any
signiﬁcant difference between two study groups. The p-values were
0.376 and 0.568 respectively.- Cardia 6 (27.3%) 12 (23.1%) 18 (24.3%) 0.993
- Fundus 5 (22.7%) 15 (28.8%) 20 (27.0%)
- Antrum 6 (27.3%) 15 (28.8%) 21 (28.4%)
- Body 5 (22.7%) 10 (19.2%) 15 (20.3%)
Type:
- Totalb 11 (50.0%) 15 (28.8%) 26 (35.1%) 0.052
- Subtotalb 7 (31.8%) 16 (30.8%) 23 (31.1%)
- Proximalb 1 (4.5%) 0 (0.0%) 1 (1.4%)
- Laparatomy & closurec 3 (13.6%) 21 (40.4%) 24 (32.4%)
Lymphadenectomy:
- D1 19 (86.4%) 0 (0.0%) 44 (59.5%) 0.065
- D2 25 (48.1%) 6 (11.5%) 6 (8.1%)
Feeding tube placement 10 (13.5%)
Total 22 (29.7%) 52 (70.3%) 74 (100%) e
D e Lymphadenectomy; D1 includes lymphadenectomy of 3e6 levels (perigastric);
D2 includes lymphadenectomy of 1, 2 (crural) and 7, 8, 11 (lymph nodes along left
gastric, hepatic and splenic arteries respectively) in addition to levels 3e6.
a Scale and dichotomous variables are presented by mean ± SD and frequency (%)
respectively.
b Total, subtotal and proximal gastrectomy.
c In the cases of inoperable gastric tumor.
Table 3
Postoperative ﬁndings in the study patients.
Postoperative ﬁndings Case groupa Controla group Totala p-valuea
Postoperative MVS 5 (22.7%) 10 (19.2%) 15 (20.3%) 0.479
POD of extubationb 0.27 ± 0.55 0.46 ± 1.8 0.41 ± 1.6 0.504
Post-op metabolic acidosis 2 (9.1%) 4 (7.7%) 6 (8.1%) 0.794
CV-line placement 11 (50.0%) 15 (28.8%) 26 (35.1%) 0.071
NPO days 4.6 ± 1.1 3.9 ± 2.3 4.1 ± 2.0 0.053
NGT removal day 3.5 ± 1.1 3.0 ± 2.1 3.2 ± 1.9 0.268
POD of Ambulation 2.8 ± 1.1 2.7 ± 2.0 2.7 ± 1.8 0.769
Intra-op PC infusion 2 (9.1%) 10 (19.2%) 12 (16.2%) 0.236
Post-op PC infusion 2 (9.1%) 3 (5.7%) 5 (6.8%) 0.541
Reoperation 0 (0.0%) 1 (1.9%) 1 (1.4%) 0.703
In-hospital mortality 0 (0.0%) 2 (3.8%) 2 (2.8%) 0.685
Morbidity:
- Wound dehiscence 0 (0.0%) 1 (1.9%) 1 (1.4%) 0.520
- Wound infection 0 (0.0%) 0 (0.0%) 0 (0.0%)
- Bleeding 2 (9.1%) 2 (3.8%) 4 (5.6%)
- Pneumothorax 0 (0.0%) 1 (1.9%) 1 (1.4%)
Total 22 (29.7%) 52 (70.3%) 74 (100%) e
MVS e Mechanical Ventilatory Support; POD e Postoperative Day; post-op e
postoperative; CV-line e Central Venous Line; NPO e Nil per os; NGT e Nasogastric
Tube; intra-op e intraoperative.
a Scale and dichotomous variables are presented by mean ± SD and frequency (%)
respectively.
b Mean ± SD is among patients who transferred intubated to SICU after the
operation.
Table 4
TNM staging of operable study patients in case and control group based on Inter-
national Union against Cancer (IUAC) and American Joint Committee on Cancer
(AJCC).
TNM Case groupa Controla group Totala p-valuea
T1 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.596
T2 3 (15.8%) 7 (22.6%) 10 (20.0%)
T3 16 (84.2%) 23 (74.2%) 39 (78.0%)
T4 0 (0.0%) 1 (3.2%) 1 (2.0%)
N0 5 (26.3%) 3 (9.7%) 8 (16.0%) 0.376
N1 10 (52.6%) 21 (67.7%) 31 (62.0%)
N2 4 (21.1%) 6 (19.4%) 10 (20.0%)
N3 0 (0.0%) 1 (3.2%) 1 (2%)
Stage IB 1 (5.3%) 0 (0.0%) 1 (2.0%) 0.568
Stage II 5 (26.3%) 8 (25.8%) 13 (26.0%)
Stage IIIA 10 (52.6%) 17 (54.8%) 27 (54.0%)
Stage IIIB 3 (15.8%) 4 (12.9%) 7 (14.0%)
Stage IV 0 (0.0%) 2 (6.5%) 2 (4.0%)
Total 19 (38.0%) 31 (62.0%) 50 (100%) e
TNM e Tumor, Node, Metastasis.
a Presented by frequency (%).
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Neoadjuvant chemotherapy for gastric adenocarcinoma has two
different aspects in respect to the disease state. Administration of
chemotherapy regimens before surgery to patients with locally-
advanced disease may increase the possibility of a curative resec-
tion [7,13,14]. However, in resectable gastric cancers, the adminis-
tration of neoadjuvant chemotherapy focuses on survival beneﬁts
rather than resectability [7,12]. In advanced disease, the effects of
preoperative chemotherapy can be followed by computed tomog-
raphy (CT) to ensure response of primary tumor and perigastric
lymph nodes to the administered regimens [11,14]. However, in the
cases of resectable gastric cancer, potential concern exists because
delaying deﬁnite surgical resection may lead to disease progression
and unresectability [7,15,16].
In a recent study, Oki et al. evaluated the efﬁcacy and safety of
preoperative chemotherapy with docetaxel plus S-1 for resectable
advanced gastric cancer. They used pathological response rate as
the primary end point. The response rate to preoperative chemo-
therapy was 34%. The authors concluded that the combination of
docetaxel and S-1 is promising as a preoperative chemotherapy
regimen for patients with potentially resectable advanced gastric
cancer [17].
In a retrospective analysis by Del Rio et al., nine patients out of
93 with advanced gastric cancer received chemotherapy before
surgical resection. The authors' experience showed that the neo-
adjuvant therapy can reduce staging and increase the R0 resection.
They suggested that it should be proposed in young patients with
low comorbidity [18].
In a randomized double-blinded controlled trial performed at
the Firoozgar hospital in Tehran, Basi et al. compared efﬁcacy of
preoperative neoadjuvant chemotherapy and surgery versus sur-
gery alone in patients with resectable gastroesophageal cancer.
They showed that combination of chemotherapy and surgery
compared to surgery alone improved R0 resection status, but mid-
term survival rate was similar in the two groups. They concluded
that R0 resection status can effectively predict appropriate mid-
term survival in undertreated patients [19].Nagahama et al. evaluated the outcome of preoperative treat-
ment with S-1 and cisplatin for the treatment of advanced gastric
cancer. Preoperative treatment with S-1 and cisplatin was not only
an effective initial treatment; it potentially accentuated tumor
regression [20]. Advanced gastric cancers which respond to initial
preoperative chemotherapy, can safely undergo curative resection
[21,22]. Some studies indicate promising results for stage IV tumor.
Although surgical resection may compromise to R1 in these cases,
survival beneﬁts in 2-year follow-up have been evident [23].
A number of other trials have also indicated the effectiveness of
neoadjuvant chemotherapy in the management of locally-
advanced gastric cancer. Kosaka et al. showed the effectiveness of
docetaxel and S-1 in locally-advanced cases in a recent clinical trial
[24]. Isobe et al. [25], Park et al. [26], Chen et al. [27], Zhang et al.
[28], Molina et al. [29] and Tsuburaya et al. [30] also reported
similar results indicating effectiveness of neoadjuvant chemo-
therapy in advanced gastric adenocarcinoma.
Promising efﬁcacies of neoadjuvant chemotherapy in gastric
cancer has been demonstrated in several clinical trials with the safe
use of radical curative surgery followed by lymphadenectomy.
However, the choice between D1 or D2 gastrectomy depends on the
institutional policies. D2 surgery is performed by experienced
surgeons and is usually conducted in Asian studies mainly from
Japan [1,20,23,30,31]. Because neoadjuvant chemotherapy is usedmostly for advanced gastric cancers, it has been proposed that D2
resection may provide some survival beneﬁts [31]. Postoperative
chemotherapy is administered for almost all patients with gastric
cancers stage II or higher. However, postoperative chemoradiation,
which is a standard treatment in North America, is only regarded as
a treatment option for patients after inadequate surgery (i.e. <D2
dissection) in many European countries [32]. According to Asian
strategies, surgery is still considered to be the mainstay for the
treatment of localized gastric cancer with negative margins (R0-
resection) and an adequate lymph-node-dissection (D2-lympha-
denectomy). The extent of surgical resection is a more favorable
strategy than postoperative adjunct modalities [33,34].
It should be declared that chemotherapy as an adjuvant therapy
may be administered postoperatively for all patients with gastric
cancers of locally-advanced or advanced stages regardless of
curative resection [1,4]. The efﬁcacy of adjuvant chemotherapy in
R0 or R1 gastric resections is not clearly established [5]. However,
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This possibly results from down-staging, primary tumor shrinkage,
attenuation of lymph node involvement and differentiating surgical
planes by tumor regression and regeneration of fad pads
[7,11,32e34]. For this reason, resectability should be considered a
potential primary output when neoadjuvant chemotherapy is
administered. However, survival analysis should prospectively
prove beneﬁcial effects of chemotherapy regimens [31].
Although a number of trials suggest that neoadjuvant chemo-
therapy affords beneﬁcial effects in locally-advanced cases of
gastric adenocarcinoma, the standard treatment of gastric cancer in
any stage is surgical resection unless preoperative CT suggests
distant metastasis [1,4,7]. Considering conclusive clinical trials and
evidence-based studies, preoperative staging and subsequent
neoadjuvant therapies are becoming standard approaches for
locally-advanced gastric cancers in some centers [7,27,29].
In the present study, we wanted to assess the effect of neo-
adjuvant chemotherapywith docetaxel, cisplatin and 5-ﬂuorouracil
on patients with locally-advanced gastric adenocarcinoma. During
a preliminary clinical trial, we aimed to evaluate the effects of this
neoadjuvant chemotherapy regimen on (a) local regression of tu-
mor and involved lymph nodes and (b) the rate of resectability of
locally-advanced gastric tumors (R0 gastrectomy).
The results of this study revealed that neoadjuvant chemo-
therapy by combined docetaxel, cisplatin and 5-ﬂuorouracil
regimen potentially increases the rate of resectability in patients
with locally-advanced gastric adenocarcinoma. In addition, atten-
uation of primary tumor spread and perigastric lymph node
involvement after neoadjuvant chemotherapy was considerable.
All the resections in our series in case and control groups were
R0. Thus, it is evident that neoadjuvant chemotherapy has poten-
tially increased the rate of curative resection. Del Rio et al. also
reported an increase in the rate of R0 resection in their retrospec-
tive analysis of advanced gastric cancer patients who received
neoadjuvant chemotherapy [18]. Patel & Kooby assessed 12 studies
on neoadjuvant chemotherapy in gastric cancer. According to their
analysis, patients who received neoadjuvant chemotherapy had a
marginal improvement in overall survival compared to the control
group. Three studies out of twelve found 3-year progression-free
survival to be higher in the neoadjuvant compared with the con-
trol group. A signiﬁcant down-staging effect was also seen in the
neoadjuvant group compared with controls, and complete resec-
tion (R0) was found to be higher in the neoadjuvant group [7].
Another study by Lowy et al. reported higher survival rates for
patients who received neoadjuvant chemotherapy [35].
In a subgroup analysis by Li et al., it was revealed that patients
who had gastric cancer with later stages of disease (pT3e4)
beneﬁted more from neoadjuvant therapy than those at earlier
stages (pT1e2) when overall survival rate was the end point and
monotherapy was inferior to combination therapy regimens [36].
Thus, it is of potential importance that patients with locally-
advanced disease are likely to beneﬁt more from neoadjuvant
chemotherapy. We have included only patients with locally-
advanced disease because we hypothesized that neoadjuvant
intervention may diminish tumor extent and increase the possi-
bility of curative resection. Administration of neoadjuvant chemo-
therapy to patients with advanced disease is safe. The primary
indication of trial enrollment for neoadjuvant therapy is T3 and N
positive tumors [1]. Even with T4 tumors, the delay of surgical
resection for administration of neoadjuvant chemotherapy is
acceptable because unresectable gastric tumors may have likely
been beyond surgical therapy at presentation [7].
It has been accepted that surgery is the only curative treatment
in gastric cancer. It is also accepted that the surgeon should avoid
surgical nihilism and do not deprive the patient from surgery [1].Thus, increasing the rate of resectable cases in gastric locally-
advanced adenocarcinoma is of potential clinical interest. Howev-
er, survival analyses showmarginal beneﬁts in favor of neoadjuvant
chemotherapy and prospective analysis of locally-advanced gastric
cancer patients is strongly warranted. Moreover, the endpoint
should be outlined. Three-year disease free survival seems to
improve more than overall survival by administration of neo-
adjuvant chemotherapy [7]. Because surgery is the only curative
modality in gastric cancer, we considered resectability as the pri-
mary endpoint in this preliminary clinical trial. Future prospective
follow-up of patients is of potential interest and will be conducted
by principal investigator of this study in the following years.
Preoperative staging is necessary for precise decision making
especially when preoperative chemotherapy is planned. Endo-
scopic Ultrasound (EUS) is the modality of choice for preoperative
radiological staging. EUS can determine tumor size (T) and assess
perigastric lymph node involvement (N) [4]. Preoperative abdom-
inal CT scan is done for all gastric cancer patients [1,4,5]. Preoper-
ative CT has been recently used successfully for detection of
perigastric lymph node involvement. In addition, control CT scans
after courses of neoadjuvant chemotherapy may illustrate primary
tumor shrinkage and perigastric attenuation of positive lymph
nodes [6,14,16]. In the present study, we used preoperative CT to
detect perigastric involvement. Control CTs had promising results
in illustrating tumor regression by neoadjuvant chemotherapy.
Adjuvant chemotherapy is administered for gastric cancer pa-
tients with stage II or higher [1]. The therapeutic beneﬁts of this
strategy is not understood completely yet [6]. However, a number
of studies suggest that adjuvant chemotherapy should be admin-
istered to patients with positive lymph nodes on histopathological
analysis, i.e., pN positive tumors. In addition, the extent of lym-
phadenectomy is another issue. Some experienced surgeons
conduct D2 gastrectomy. It seems that adjuvant chemotherapymay
not be necessary in patients who undergo D2 resection [7]. Adju-
vant therapy is essential in patients who undergo R1 or R2 resection
or in inoperable cases [5]. In our study, we did gastrectomy in 50
patients in case and control groups. Forty-four patients (88%) un-
derwent D1 gastrectomy while six patients (12%) underwent D2
gastrectomy.
In the mentioned study from Iran, Basi et al. studied neo-
adjuvant chemotherapywith docetaxel, cisplatin and 5-ﬂuorouracil
in patients with resectable gastric cancer. According to their results,
neoadjuvant chemotherapy could increase R0 resection. They also
reported signiﬁcant down-staging in T and N states after preoper-
ative chemotherapy [19]. We studied effectiveness of neoadjuvant
chemotherapy by the same regimen on locally-advanced gastric
cancers. Advanced gastric adenocarcinomas are inoperable in some
cases and patients undergo unnecessary laparotomy [5,6]. It is not
possible to determine the resectability precisely to avoid surgical
exploration. However, by considering this possibility, curative
treatment in probable inoperable gastric tumors may be provided
by preoperative neoadjuvant modalities. Thus, we assessed the
effects of neoadjuvant chemotherapy on resectability of gastric
locally-advanced tumors while Basi et al. [19] aimed to increase R0
resection to improve survival. The distinction between resectability
during laparotomy and R0 resection should be considered because
different patient subgroups are treated in each category.
In another study, Brenner et al. administered neoadjuvant cis-
platineﬂuorouracil followed by postoperative intraperitoneal
ﬂoxuridineeleucovorin to patients with locally advanced gastric
cancer. They stated that these regimens were safely delivered to
patients undergoing radical gastrectomy and D2 lymphadenec-
tomy. According to their results, the R0 resection and the survival
rates were encouraging [37]. Basi et al. also indicated an increase in
R0 resection by neoadjuvant chemotherapy [19] but Brenner and
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We studied the outcome of patients with locally-advanced disease
similar to the study of Brenner and colleagues. They treated thirty-
eight patients and both preoperative and postoperative chemo-
therapy were administered and all the patients had resectable tu-
mors. However, three patients (13.6%) who delivered preoperative
chemotherapy had unresectable tumors in our study. It may be due
to unavailability of EUS to exclude stage IV tumors by T4 size.
Advanced gastric tumors with extensive adjacent invasion may
constitute a different subgroup of patients that should undergo
appropriate preoperative strategies different from locally-advanced
cases.
This study suggests that neoadjuvant chemotherapy can in-
crease resectability rate in patients with locally-advanced adeno-
carcinoma. To distinguish locally-advanced gastric tumors, CT scan
may offer useful diagnostic beneﬁts. Preoperative CT may detect
perigastric lymph node involvement and mural involvement.
Neoadjuvant chemotherapy can attenuate primary tumor size and
lymph node involvement in patients with locally-advanced gastric
adenocarcinoma. It can be detected radiologically by follow-up CT
scans. However, beneﬁts of neoadjuvant chemotherapy are of po-
tential clinical interest and precise determination of locally-
advanced cases with exact preoperative techniques such as EUS is
warranted.
The present study illustrates that neoadjuvant chemotherapy
increases curability of locally-advanced gastric cancer patients
because surgical resection is the only curative treatment for gastric
cancer. However, it should be addressed that beneﬁcial effects of
neoadjuvant chemotherapy in this setting should be conﬁrmed by
prospective trials to evaluate disease free and overall survival rates
of patients treated by neoadjuvant chemotherapy and surgery
versus surgery alone. In addition, preoperative staging should be
done precisely by the use of EUS to allocate subgroups of locally-
advanced gastric adenocarcinomas to chemotherapy regimens of
different combinations and durations. Then, prospective follow-up
of subgroups may determine patients who get more survival ben-
eﬁts from neoadjuvant chemotherapy. Moreover, precise preoper-
ative staging may distinguish patients who beneﬁt more from early
surgical resection rather than neoadjuvant chemotherapy.
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